Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
A Susin, Santos
2023 - Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Santos A Susin
Favorite
Abada, Paolo

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Paolo Abada
Favorite
Abdallah, Ali
1045 - LYN kinase programs stromal fibroblasts to facilitate leukemic survival via regulation of c-JUN and THBS1
Ali Abdallah
Favorite
Abdel-Wahab, Omar

Memorial Sloan Kettering Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Omar Abdel-Wahab
Favorite
Abhyankar, Sarang

Loxo@Lilly
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Sarang Abhyankar
Favorite
Abohadi, Saleh
1112 - Immunophenotyping of Chronic Lymphocytic Leukemia in Yemen.
Saleh Abohadi
Favorite
Abramson, Jeremy

Massachusetts General Hospital Cancer Center
2016 - Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with chronic lymphocytic leukemia: Impact of early MRD kinetics on posttreatment outcomes
Jeremy Abramson
Favorite
Abrisqueta, Pau

Vall d'Hebron Institute of Oncology (VHIO)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Pau Abrisqueta
Favorite
Agami, Orel

Weill Cornell Medicine
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
Orel Agami
Favorite
Agathangelidis, Andreas
1009 - IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Andreas Agathangelidis
Favorite
Agius, Rudi

Department of Hematology, Rigshospitalet, Copenhagen University Hospital
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Rudi Agius
Favorite
Ahmad, Mohammad

Ascentage Pharma Group Inc.
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Mohammad Ahmad
Favorite
Ahmmad-Ud-Din, Mohammad

H Lee Moffitt Cancer Center & Research Institute
1026 - Targeting the pro-inflammatory protein S100-A9 in Chronic Lymphocytic Leukemia
Mohammad Ahmmad-Ud-Din
Favorite
Ailawadhi, Sikander

Department of Cancer Biology, Mayo Clinic
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Sikander Ailawadhi
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Sikander Ailawadhi
Favorite
Aitken, Casey

Division of Hematology, Mayo Clinic
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Casey Aitken
Favorite
Aittokallio, Tero

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Tero Aittokallio
Favorite
1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
Tero Aittokallio
Favorite
Akbar, Sitara

University of Oxford, Department of Oncology
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Sitara Akbar
Favorite
Akinola, Norah O.

Obafemi Awolowo University Teaching Hospital
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Norah O. Akinola
Favorite
Al Essa, Wael

ivision of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Wael Al Essa
Favorite
Alapi, Hilel
1140 - Pregnancy course of 10 women diagnosed with Chronic Lymphocytic Leukemia
Hilel Alapi
Favorite
Albi, Elisa

IRCCS Ospedale San Raffaele
2015 - VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
Elisa Albi
Favorite
Albiol, Nil

Catalan Institute of Oncology (ICO) Girona
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Nil Albiol
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Nil Albiol
Favorite
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Nil Albiol
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Nil Albiol
Favorite
Alcoceba, Miguel

Centro de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC)
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Miguel Alcoceba
Favorite
Aldaout, Ali

Practice MVZ Mitte am Johannisplatz, Leipzig
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Ali Aldaout
Favorite
Alhasani, Hasan

AbbVie
1143 - The Economic Benefits of Time Off Treatment: Real-World HRU, Costs, and Subsequent Treatment with Fixed Duration Venetoclax among Patients with Chronic Lymphocytic Leukemia
Hasan Alhasani
Favorite
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Hasan Alhasani
Favorite
Allan, John

Weill Cornell Medicine
1207 - A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naïve chronic lymphocytic leukemia
John Allan
Favorite
3002 - Zanubrutinib and venetoclax as initial therapy for CLL with obinutuzumab triplet consolidation in patients with minimal residual disease positivity (BruVenG)
John Allan
Favorite
Allen, Steven L.

Zucker School of Medicine at Hofstra/Northwell
1003 - Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.
Steven L. Allen
Favorite
Almasri, Mohammad

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Mohammad Almasri
Favorite
Almuhanna, Hassan

School of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow
1027 - B cell receptor-mediated signals modulate rapid FOXO1 upregulation in chronic lymphocytic leukaemia: a role for deubiquitinate proteins?
Hassan Almuhanna
Favorite
Alpar, Donat
1163 - Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia
Donat Alpar
Favorite
Al-Sawaf, Othman

Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
1212 - Targeted agents in chronic lymphocytic leukemia (CLL): Data on outcomes and subsequent therapies of patients observed within the German CLL Study Group (GCLLSG) registry
Othman Al-Sawaf
Favorite
2012 - Matching-Adjusted Indirect Comparison of Pirtobrutinib vs Venetoclax Continuous Monotherapy in Patients with Relapsed/Refractory CLL Previously Treated with a Covalent BTK Inhibitor
Othman Al-Sawaf
Favorite
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Othman Al-Sawaf
Favorite
Alvarez, Diego

University of Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Diego Alvarez
Favorite
Alvarez, Hermy

Universidad de Magallanes
1032 - Clonal Space Assessment in Chronic Lymphocytic Leukemia Using an Unbiased NGS Approach
Hermy Alvarez
Favorite
Ambrose, Jacob

COTA, Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Jacob Ambrose
Favorite
Ammad Ud Din, Mohammad

H Lee Moffitt Cancer & Research Institute
1119 - Treatment Strategies and Outcomes for Double Refractory chronic lymphocytic leukemia; A single center experience
Mohammad Ammad Ud Din
Favorite
Andel, Johannes

Department of Internal Medicine II, Pyrn-Eisenwurzen Klinikum Steyr
1205 - Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Long Term Follow up of the International Randomized AGMT-CLL8/a Mabtenance Trial
Johannes Andel
Favorite
Anderson, Mary Ann

Department of Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre
1150 - Past informs the future: outcomes post allogeneic stem cell transplantation in high risk chronic lymphocytic leukaemia (CLL)
Mary Ann Anderson
Favorite
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Mary Ann Anderson
Favorite
Andersson, Maria

Department of oncology-pathology, Karolinska Institutet, Stockholm, Sweden; Lymphoma Unit, Karolinska University Hospital
2001 - Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia
Maria Andersson
Favorite
Andersson, P-O

Section of Hematology and Coagulation, Department of Specialist Medicine, Sahlgrenska University Hospital
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
P-O Andersson
Favorite
Andreu, Rafael

Hospital Universitario Politécnico "La Fe"
1111 - Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Rafael Andreu
Favorite
Andric, Jelena

University Hospital Dubrava
1130 - Vertebral fractures in patients with B-cell chronic lymphocytic leukemia before and after ibrutinib treatment
Jelena Andric
Favorite
An, Gang

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Gang An
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Gang An
Favorite
Angeli, Antonia

University of Heidelberg
1057 - Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures
Antonia Angeli
Favorite
Aoki, Sadao

Niigata University of Pharmacy and Applied Life Sciences
1126 - Significance of sIL-2R and LD in predicting time to first treatment in Japanese CLL patients with early asymptomatic disease.
Sadao Aoki
Favorite
Appleby, Niamh

Oxford Molecular Diagnostic Centre, Department of Oncology, University of Oxford
1202 - T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study
Niamh Appleby
Favorite
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Niamh Appleby
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Niamh Appleby
Favorite
Arenas, Fabian

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain;
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Fabian Arenas
Favorite
Arenas, Víctor

Instituto de Investigación Marqués de Valdecilla (IDIVAL)
1043 - Regulation of the NF-kB pathway by NEDDylation in chronic lymphocytic leukemia: Beyond IkB
Víctor Arenas
Favorite
Arguello-Tomas, Miguel

HOSPITAL SANTA CREU I SANT PAU
1104 - Non-Hematological Autoimmune Disorders are frequent in CLL, but are they clinically related? Data from a Single-center Real-Life Cohort
Miguel Arguello-Tomas
Favorite
1117 - EVOLUTION IN THE FRONTLINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: EXPERIENCE FROM ONE EUROPEAN CENTER
Miguel Arguello-Tomas
Favorite
1118 - Similar discriminatory values of IPS-E, AIPSE, and CR0 scores predicting time to first treatment in a large series of unselected patients with early-stage CLL
Miguel Arguello-Tomas
Favorite
1129 - Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Miguel Arguello-Tomas
Favorite
Arnold, Zachary

The Ohio State University Comprehensive Cancer Center
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Zachary Arnold
Favorite
Arpas, Tomas

Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital
1010 - The interplay between BcR signaling and the p53 pathway upon DNA damage in primary CLL cells
Tomas Arpas
Favorite
Arrais-Rodrigues, Celso

Hospital Nove de Julho / DASA
1227 - Concomitant use of venetoclax 100 mg and ketoconazole to treat CLL in a public center in Brazil
Celso Arrais-Rodrigues
Favorite
Arribas, Alberto J.

Institute of Oncology Research, Faculty of Biomedical Sciences, USI
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Alberto J. Arribas
Favorite
Ashton, John

University of Rochester School of Medicine and Dentistry
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
John Ashton
Favorite
Ashworth, Iona

Brighton and Sussex Medical School
1005 - Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.
Iona Ashworth
Favorite
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Iona Ashworth
Favorite
Assouline, Sarit

McGill University, Jewish General Hospital, Montreal
2002 - Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Sarit Assouline
Favorite
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Sarit Assouline
Favorite
Aszyk, Christoph
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Christoph Aszyk
Favorite
Athanasiadis, Paschalis

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
1052 - PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Paschalis Athanasiadis
Favorite
Athlin, Simon

School of Medical Sciences, Faculty of Medicine and Health, Örebro University
1154 - Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Simon Athlin
Favorite
Atwal, Siminder

Prelude Therapeutics
2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies
Siminder Atwal
Favorite
Auguin, Daniel
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Daniel Auguin
Favorite
Aumont, Pierre

ELLyE (Ensemble Leucémie Lymphomes Espoir)
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Pierre Aumont
Favorite
1147 - Global Perspectives through multi stakeholder mapping of lived experience with CLL – insights to improve equity, services, and unmet need
Pierre Aumont
Favorite
Aurer, Igor

University Hospital Centre Zagreb and Medical School, University of Zagreb
1124 - Efficacy and toxicity of ibrutinib in CLL - Croatian experience. A non-interventional, real world study of KroHem
Igor Aurer
Favorite
1225 - Real-world evidence on venetoclax in chronic lymphocytic leukemia: The KROHEM (Croatian cooperative group for hematological diseases) experience
Igor Aurer
Favorite
Aurran, Thérèse

Institut Paoli Calmettes
1211 - Venetoclax as an Alternative and Effective Treatment in Central Nervous System Involvement of Chronic Lymphocytic Leukemia: Monocentric Experience
Thérèse Aurran
Favorite
1218 - Lenalidomide Consolidation Improves Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - Final Analysis of CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)
Thérèse Aurran
Favorite
1221 - Occurrence and Evolution of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia Patients treated with Venetoclax: a study of the French Innovative Leukemia Organization (FILO).
Thérèse Aurran
Favorite
Autore, Francesco

Fondazione Policlinico Universitario A. Gemelli IRCCS
1201 - Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Francesco Autore
Favorite
1203 - Chronic obstructive pulmonary disease and previous infections have impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a multicentre SEIFEM study.
Francesco Autore
Favorite
1219 - The evolution of treatments and outcome of patients with chronic lymphocytic leukemia treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: a monocentric experience of the Last 30 Years.
Francesco Autore
Favorite
1222 - KINETICS OF LYMPHOCYTOSIS DURING BTK COVALENT INHIBITORS IN TREATMENT NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
Francesco Autore
Favorite
Awikeh, Bassel

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale
1007 - XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling
Bassel Awikeh
Favorite
Aymerich, Marta

Hospital Clínic de Barcelona
4001 - Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation
Marta Aymerich
Favorite